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The World Health Organisation (WHO) estimates that 20%
of the world population now suffers from allergic diseases
(1), but this epidemic is no longer restricted to developed
countries: low and lower-middle income countries experience
over 80% of asthma deaths worldwide (2).
Many factors may be involved in the global increase in
allergic disease, but the declining incidence and prevalence of
infectious diseases is widely considered to be an important
contributor (3). Chronic worm infections may particularly
protect against allergy (4). During established infections,
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Abstract
Background: Allergy is commoner in developed than in developing countries.
Chronic worm infections show inverse associations with allergy, and prenatal expo-
sures may be critical to allergy risk.
Objective: To determine whether anthelminthic treatment during pregnancy
increases the risk of allergy in infancy.
Methods: A randomised, double-blind, placebo-controlled trial on treatment in preg-
nancy with albendazole versus placebo and praziquantel versus placebo was con-
ducted in Uganda, with a 2 · 2 factorial design; 2507 women were enrolled; infants’
allergy events were recorded prospectively. The main outcome was doctor-diagnosed
infantile eczema.
Results: Worms were detected in 68% of women before treatment. Doctor-diag-
nosed infantile eczema incidence was 10.4/100 infant years. Maternal albendazole
treatment was associated with a signiﬁcantly increased risk of eczema [Cox HR
(95% CI), p: 1.82 (1.26–2.64), 0.002]; this effect was slightly stronger among infants
whose mothers had no albendazole-susceptible worms than among infants whose
mothers had such worms, although this difference was not statistically signiﬁcant.
Praziquantel showed no effect overall but was associated with increased risk among
infants of mothers with Schistosoma mansoni [2.65 (1.16–6.08), interaction
p = 0.02]. In a sample of infants, skin prick test reactivity and allergen-speciﬁc IgE
were both associated with doctor-diagnosed eczema, indicating atopic aetiology.
Albendazole was also strongly associated with reported recurrent wheeze [1.58
(1.13–2.22), 0.008]; praziquantel showed no effect.
Conclusions: The detrimental effects of treatment suggest that exposure to maternal
worm infections in utero may protect against eczema and wheeze in infancy. The
results for albendazole are also consistent with a direct drug effect. Further studies
are required to investigate mechanisms of these effects, possible beneﬁts of worms
or worm products in primary prevention of allergy, and the possibility that routine
deworming during pregnancy may promote allergic disease in the offspring.
Pediatric Allergy and Immunology
Pediatric Allergy and Immunology 22 (2011) 305–312 ª 2011 John Wiley & Sons A/S 305
worms evoke strong immunoregulation, protecting themselves
against host responses, for example, by eliciting regulatory
cytokines such as interleukin (IL)-10 and transforming
growth factor (TGF-) b. ‘Bystander’ effects of these processes
may down-regulate responses to other immunogens, including
allergens (5). In humans, several cross-sectional studies have
demonstrated inverse associations between chronic worm
infections and atopy (6,7), and initial intervention studies
suggested that regular anthelminthic treatment was associated
with increased skin prick reactivity (8). However, a large trial
among school children in Ecuador showed no such effect: if
worm infections protect against allergy, their effect, at least
on skin prick reactivity, could not readily be reversed at this
age (9). One contributory explanation to this paradox could
be that long-term, worm-mediated effects are established ear-
lier in life, and indeed, there is considerable evidence that
prenatal exposures are critical to later susceptibility to aller-
gic disease (10).
Worm infections during pregnancy also have important
immunological effects on the offspring, including sensitisation
to worm antigens (11), long-term effects on the response to
infection with the same worm species (12), and modiﬁcation
of responses to unrelated vaccine antigens (13). Whether
worm infections during pregnancy inﬂuence the response to
allergens or development of allergy in the offspring is not
known. This question is particularly topical in view of cur-
rent promotion of policies for deworming during pregnancy
WHO recommended mass treatment for soil transmitted
helminths during pregnancy (with drugs including albenda-
zole) in areas where the prevalence of hookworm is more
than 20% in 1994 (14) and the use of praziquantel for treat-
ment of schistosomiasis in pregnancy in 2002 (15), with the
subsequent provision that this should be investigated in pla-
cebo-controlled trials (16).
Our preliminary study showed a reduced risk of eczema
among infants whose mothers had worms and suggested an
increased incidence among infants of mothers who received
albendazole during pregnancy compared to infants whose
mothers received placebo (17). We now present results of a
large randomised-controlled trial of treatment during preg-
nancy with albendazole and praziquantel, addressing the
hypothesis that worm infections during pregnancy protect
against allergic diseases in infancy and that treatment of
worms during pregnancy increases their incidence.
Methods
Setting and participants
The study has been described [ISRCTN32849447] (18). It was
conducted in Wakiso district, Uganda. Pregnant women
attending Entebbe Hospital (a free Government hospital serv-
ing most of the local community) for their ﬁrst antenatal visit
between April 2003 and November 2005 were screened for
enrolment. Women were eligible if they were well, in their
second or third trimester, resident in the study area, planning
delivery at Entebbe Hospital, willing to participate and will-
ing to know their HIV status and excluded if they had hae-
moglobin <8 g/dl, clinically apparent severe liver disease,
diarrhoea with blood in the stool, abnormal pregnancy, his-
tory of adverse reaction to anthelminthic drugs, or had par-
ticipated in the study during an earlier pregnancy. All
participants gave informed written consent.
The study was approved by ethics committees of the
Uganda Virus Research Institute and London School of
Hygiene and Tropical Medicine, and by the Uganda National
Council for Science and Technology.
Study design
This was a randomised, double-blind, placebo-controlled trial
of antheminthics in pregnancy, using albendazole versus
placebo and praziquantel versus placebo in a 2 · 2 factorial
design. Prior to enrolment, participants provided a single
stool and blood samples for parasitology and other investiga-
tions. At enrolment, they were allocated to one of the four
treatment arms (albendazole + praziquantel, albendazole +
praziquantel-placebo, albendazole-placebo + praziquantel,
albendazole-placebo + praziquantel-placebo) according to a
random sequence generated in blocks of 100 by the trial stat-
istician. Albendazole tablets (or matching placebo) and 12
capsules of praziquantel (or matching placebo) were provided
in sealed, identical, opaque envelopes, labelled according to
the allocation sequence, and used sequentially to administer a
single dose of albendazole (400 mg) (or placebo) and of pra-
ziquantel (40 mg/kg) (or placebo) under observation by study
staff. Participants and staff were blinded to treatment alloca-
tion. Following delivery, all women provided another stool
sample to assess the effect of therapy. At 6 wk post-delivery,
all women received albendazole and praziquantel and addi-
tional treatment for speciﬁc worm species, such as Strongylo-
ides, if required. Infants were seen at 6, 10 and 14 wk, 6, 9
and 12 months and at interim illness events.
Outcomes
The study was originally designed to examine the effects of
anthelminthic treatment during pregnancy on infant
responses to immunisation and infectious disease incidence.
However, data on all illness events, including doctor-diag-
nosed allergy, were collected from the start of the trial and
reported allergy outcomes were added to the 1-yr visit ques-
tionnaire before any participating child had reached age 1 yr,
in response to our initial ﬁndings (17), as a second source of
allergy information used widely in epidemiological studies
(19). Therefore, allergic disease outcome information was col-
lected by two methods. (i) Doctor-diagnosed allergic events
were recorded prospectively at routine or interim clinic visits
and were either the presenting complaints or noted inciden-
tally in children presenting for other reasons. The primary
outcome was eczema, the most common allergic condition in
infancy (17), deﬁned as a recurrent itchy rash, with dry/scaly
or wet/weeping skin, and with typical infant distribution.
Doctors received support in practical dermatological diagno-
sis from the national referral hospital. (ii) Reported allergic
events were secondary outcomes, documented during the 1-yr
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clinic visit by interviewing the mother or guardian using the
International Study of Asthma and Allergies in Childhood
(ISAAC) questionnaire (19). Data on eczema, wheeze and
urticaria were collected. The ISAAC questionnaire was
modiﬁed for infants by replacing ‘speech’ with ‘feeding’ and
‘exercise’ with ‘playing’. We excluded allergic rhinitis because
of the difﬁculty in correctly distinguishing it from common
colds and included urticaria for which we could obtain a
clear history in the local language.
Skin prick testing and allergen-specific IgE assays
A systematic sample of infants attending clinic visits at age
1 yr was selected to undergo skin prick testing (SPT) between
September 2006 and April 2007. Subsequently, stored sera
from the same infants, and obtained at the same visit, were
examined for allergen-speciﬁc IgE. This data was used to
assess whether infantile eczema diagnosed in this study was
likely to be atopic.
Skin prick testing was carried out using standard proce-
dures (20), with four allergens important in this setting (6) or
in childhood: dust mites (Dermatophagoides mix (D. farina,
D. pteronyssinus); Blomia tropicalis), eggs and cow’s milk.
To measure allergen-speciﬁc Immunoglobulin (Ig)E, 384-
well high binding microplates (Greiner bio-one Ltd, Stone-
house, UK) were coated with 15 ll/well 2 lg/ml dustmite
mixture (D. farina, D. pteronyssinus) or cockroach (Blattella
germanica) (Greer Labs, Lenoir, NC, USA) in 20 mm sodium
bicarbonate/27 mm sodium carbonate buffer pH 9.6. Plates
were washed four times with phosphate-buffered saline
(PBS) + 0.03% Tween 20 (Sigma-Aldrich Company Ltd,
Dorset, UK) and blocked with 1% w/v dried milk powder in
PBS + 0.05% Tween 20. Serum samples (1/20 in
PBS + 0.05% Tween 20 + 10% heat inactivated bovine calf
serum) and standards were tested in duplicate. Threefold
serial dilutions of speciﬁc IgE positive sera, standardised
using the Immunocap assay system (Phadia, Uppsala, Swe-
den), formed 14 point standard curves. To six-time washed
plates, 0.5 lg/ml of biotinylated monoclonal mouse anti-
human IgE (clone G7-26; BD Pharmingen, Oxford, UK) was
added and incubated overnight at 4C, followed by 1/3000
streptavidin-conjugated polyclonal antibody-Horseradish Per-
oxidise (Mast Group Ltd, Bootle, UK), and ﬁnally 0.1 mg/ml
o-phenylenediamine (Sigma-Aldrich Co. Ltd) in 0.05 m phos-
phate-citrate buffer, pH 5.0 containing 0.03% hydrogen per-
oxide. After the addition of 2 m sulphuric acid, plates were
read at 490 and 630 nm dual wave length, and results inter-
polated from standard curves using a ﬁve parameter curve ﬁt
using Gen5 data collection and analysis software (BioTek
Instruments Inc, Vermont, Winooski, USA).
Parasitology
Stool samples were examined using charcoal culture for
Strongyloides stercoralis and Kato-Katz method (18). Two
Kato-Katz smears for each sample were read within 30 min of
preparation for hookworm and after 12 h for other parasite
ova. Blood was examined for Mansonella perstans using a
modiﬁed Knott’s method (18). Participants were deﬁned as
positive for a given infection if ova or parasites were seen.
Statistical methods
Power calculations were made using disease and loss to fol-
low-up rates from our preliminary study (17). With recruit-
ment of 2500 women for the main trial, we expected 1860
person-years (pyrs) follow-up among infants. We expected an
incidence of eczema of 25 per 100 pyr in the placebo group
for either albendazole or praziquantel. This would give 80%
power to detect an increase in eczema at p < 0.05 with rate
ratio of 1.28 for either intervention.
The trial analysis was by intention to treat. Data were
analysed using STATA version 10 (Stata Corp., College Sta-
tion, TX, USA). For doctor-diagnosed outcomes, time at risk
began at birth and was censored at death, loss to follow-up
or at 364 days. The effect of treatment on incidence of aller-
gic conditions was assessed using Cox regression analysis,
with robust standard errors to adjust for clustering within
children. Logistic regression was used to assess the effect of
anthelminthic treatment on reported outcomes. Wald tests
were used to assess for interactions between treatments. IgE
data (transformed to log(IgE + 1) to correct skewness) and
SPT positivity were each related to clinical allergy incidence
by Cox regression, with robust standard errors.
Rates or prevalence of allergic conditions were ﬁrst com-
pared between treatment groups for the whole study popula-
tion. Pre-speciﬁed subgroup analyses were conducted as
effects were expected to be stronger when mothers had sus-
ceptible infections: albendazole versus placebo among women
with hookworm; praziquantel versus placebo among women
with Schistosoma mansoni. Differences between subgroups
were examined by ﬁtting interaction terms and applying
Wald tests. All p-values are two sided with no adjustment for
multiple comparisons.
Results
Recruitment and follow-up ﬁgures are presented in Fig. 1:
2507 study women were enrolled and 2201 person-years of
follow-up observed among their infants.
Baseline characteristics of mothers and infants were similar
across the four treatment arms (Table 1). The prevalence of
worms among the pregnant women has been reported (21):
44.5% had hookworm, 21.3% M. perstans, 18.3% S. manson-
i, 12.3% S. stercoralis, 9.1% Trichuris trichiura, 2.3% Ascaris
lumbricoides and 0.5% other worms. Only 31.7% had no
detected worm infection. Examination of stool samples
obtained at delivery showed that hookworm and A. lumbrico-
ides were effectively treated by albendazole (efﬁcacy assuming
no re-infection between treatment and delivery of 88% and
82%, respectively); S. mansoni was effectively treated by pra-
ziquantel (efﬁcacy assuming no re-infection 78%); neither
treatment showed signiﬁcant effects on prevalence of M. per-
stans, S.stercoralis or Trichiuris trichiura (22). Serious adverse
events (miscarriages, stillbirths, perinatal deaths, congenital
anomalies) were not associated with either treatment (22).
Mpairwe et al. Deworming in pregnancy and allergy risk
Pediatric Allergy and Immunology 22 (2011) 305–312 ª 2011 John Wiley & Sons A/S 307
Doctor-diagnosed outcomes
Doctor-diagnosed infantile eczema was the primary outcome
and most common allergic condition with an incidence of
10.4/100 person-years of follow-up (pyrs). Rates of other
potentially allergy-related conditions were as follows: recur-
rent wheeze 0.95/100 pyrs, urticaria 1.5/100 pyrs, allergic con-
junctivitis 1.3/100 pyrs, contact dermatitis 1.0/100 pyrs and
Assessed for eligibility 
(n = 11,783)
Excluded (n = 9268)
Not meeting inclusion criteria (n = 7706)
Refused to participate (n = 874)
Other reasons (n = 688)
Allocated to praziquantel & 
placebo (n = 628) Allocation
Analysis at 
one year
Allocated to praziquantel & 
albendazole (n = 628)
Allocated to albendazole and 
placebo (n = 629)
Allocated to the two placebo only 
(n = 630)
Double enrolment (n = 0)
Haemoglobin<8 (n = 2)
Lost to follow-up before delivery 
(n = 31)
Miscarriage (n = 4)
Analyzed for doctor-diagnosed 
outcomes (n = 587)
Analyzed for reported outcomes 
at 1-year (n = 431)
Double enrolment (n = 2)
Haemoglobin<8 (n = 0)
Lost to follow-up before delivery 
(n = 31)
Miscarriage (n = 4) 
Analyzed for doctor-diagnosed 
outcomes (n = 592)
Analyzed for reported outcomes 
at 1-year (n = 427)
Double enrolment (n = 4)
Haemoglobin<8 (n = 0)
Lost to follow-up before delivery 
(n = 34)
Miscarriage (n = 6)
Analyzed for doctor-diagnosed 
outcomes (n = 583)
Analyzed for reported outcomes 
at 1-year(n = 437) 
Double enrolment (n = 2)
Haemoglobin<8 (n = 0)
Lost to follow-up before delivery 
(n = 35)
Miscarriage (n = 4)
Analyzed for doctor-diagnosed 
outcomes (n = 583)
Analyzed for reported outcomes 
at 1-year (n = 427)
Deliveries (n = 591)
Births (n = 599)
Stillbirths (n = 12)
Live births (n = 587)
Birth
Died or lost to follow-up before 1 
year (n = 58)
Still in follow-up but did not 
attend 1 year visit (n = 98)
Deliveries (n = 587)
Births (n = 596)
Stillbirths (n = 13)
Live births (n = 583)
Died or lost to follow-up before 
1 year (n = 56)
Still in follow-up but did not 
attend 1 year visit (n = 100)
Deliveries (n = 585)
Births (n = 594)
Stillbirths (n = 11)
Live births (n = 583)
Died or lost to follow-up before 
1 year (n = 47)
Still in follow-up but did not  
attend 1 year visit (n = 99)
Deliveries (n = 593)
Births (n = 600)
Stillbirths (n = 8)
Live births (n = 592)
Died or lost to follow-up before 1
year (n = 69)
Still in follow-up but did not 
attend 1 year visit (n = 96)
Randomised
(n = 2515)
Figure 1 Study profile.
Table 1 The distribution of baseline characteristics among mothers of infants included in the analysis, across the four treatment arms
Baseline maternal demographic and clinical
characteristics
Praziquantel + albendazole
N = 587 n (%)
Praziquantel only
N = 583
n (%)
Albendazole only
N = 583
n (%)
Placebo only
N = 592
n (%)
Age (years) £24 338 (58) 371 (64) 369 (63) 382 (64)
>25 249 (42) 212 (36) 214 (37) 210 (36)
Education None/primary 318 (54) 316 (54) 316 (54) 328 (55)
Secondary/Tertiary 268 (46) 266 (46) 266 (46) 263 (45)
Household economic status Most poor 259 (45) 272 (48) 253 (44) 269 (46)
Least poor 318 (55) 298 (52) 321 (56) 311 (54)
HIV status Positive 71 (12) 56 (10) 63 (11) 88 (15)
Worm status At least one species 398 (69) 388 (68) 388 (67) 399 (68)
Hookworm status Positive 256 (44) 272 (47) 241 (42) 256 (43)
Schistosoma mansoni status Positive 107 (18) 97 (17) 115 (20) 102 (17)
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papular urticaria 5.6/100 pyrs. Altogether 10,252 illnesses
were recorded during infancy; total numbers of clinic visits
were similar in the four treatment arms.
We found no interaction between albendazole and praziqu-
antel treatments; therefore, we analysed the two drugs inde-
pendently; that is, we analysed the effects of albendazole
versus albendazole placebo in the whole study population
irrespective of praziquantel treatment and vice versa.
Treatment of pregnant women with albendazole (compared
with placebo) was strongly associated with an increased risk
of infantile eczema in their offspring (Table 2). In the sub-
group analysis stratiﬁed according to maternal hookworm
status, the effect of treatment with albendazole on infantile
eczema was slightly stronger among infants whose mothers
had no hookworm than among infants whose mothers had
hookworm, although this difference was not statistically sig-
niﬁcant (p-value for interaction = 0.52). In additional
exploratory analyses, the effect of albendazole was also
slightly stronger among infants whose mothers had no alben-
dazole-susceptible geohelminth (hookworm T. trichiura,
S. stercoralis and A. lumbricoides) [HR (95%CI) 1.99 (1.22–
3.24)] than among infants whose mothers had any of these
infections [1.66 (0.94–2.93)] (p-value for interaction = 0.64).
Moreover, including all geohelminths, M. perstans and
S. mansoni, there was a signiﬁcant trend of effect with total
number of worm species in the mother: the strongest effect of
albendazole was among infants whose mothers had no worm
infections at all [HR (95% CI) 2.21 (1.23–3.96)], compared
with one species [1.87 (1.04–3.35)], two species [1.42 (0.56–
3.64)] and three or more worm species [0.97 (0.19–4.86)]; test
for trend p-value = 0.002.
Treatment of pregnant women with praziquantel (com-
pared with placebo) showed no overall effect on the risk of
infantile eczema (Table 2). Among infants whose mothers
had schistosomiasis at enrolment, praziquantel was associated
with an increased risk of eczema, but praziquantel had no
effect among infants whose mothers were not infected
(p-value for interaction = 0.02).
Eighty-ﬁve per cent of hookworm infections and 65% of
S. mansoni infections were light (<1000 and <100 eggs/gram
of stool, respectively) (21). There was no statistical evidence
of an increasing effect of either albendazole or praziquantel
on rates of eczema with increasing infection intensity but this
analysis was limited by the small numbers of participants
with moderate or heavy infection intensity.
Reported outcomes
Among 1722 infants seen at the 1-yr visit, the prevalence of
each allergic condition for those with complete reported data
was eczema 12% (206/1715), recurrent wheeze 9% (155/1716)
and urticaria 5% (88/1708).
Maternal treatment with albendazole (compared with pla-
cebo) was weakly associated with reported eczema [OR (95%
CI), p-value: 1.29 (0.96–1.72), 0.09] and strongly associated
with reported recurrent wheeze [1.58 (1.13–2.22), 0.008], but
showed no effect on reported urticaria [0.99 (0.64–1.52),
0.96]. When stratiﬁed according to maternal hookworm sta-
tus at enrolment, albendazole showed no effect on reported
eczema if mothers had hookworm [OR 1.08 (0.69–1.68)] but
a slight increase if mothers had no hookworm [1.46 (0.98–
2.17), p-value for interaction = 0.10]. Reported recurrent
wheeze showed a similar trend, with albendazole showing no
effect when a mother had hookworm [1.11 (0.64–1.91)] but a
signiﬁcant effect if a mother had no hookworm [1.97 (1.27–
3.05), p-value for interaction = 0.31]. Praziquantel showed
no effect on these outcomes.
Skin Prick Test and allergen-specific IgE results
Out of 270 infants who had SPT at the 1-yr visit, 15 (6%)
were positive to any of the four allergens (Dermatophagoides
Table 2 Effects of treatment with albendazole and praziquantel during pregnancy on the incidence of eczema in infancy
Treatment
No. of
eczema events
Person-years of
follow-up (X100)
Incidence Rate
(per 100 pyrs)
Cox HR
(95% CI) p- Value
p-Value for
interaction
Albendazole treatment
Overall effect Placebo 83 10.92 7.33 1 0.002
Albendazole 148 11.09 13.35 1.82 (1.26–2.64)
Maternal Hookworm status
No (n = 1311) Placebo 51 6.01 8.49 1 0.52
Albendazole 103 6.32 16.31 1.92 (1.20–3.08)
Yes (n = 1024) Placebo 29 4.88 5.94 1
Albendazole 42 4.73 8.89 1.49 (0.81–2.74)
Praziquantel treatment
Overall effect Placebo 111 10.97 10.11 1 0.80
Praziquantel 117 11.03 10.60 1.05 (0.73–1.50)
Maternal Schistosoma mansoni status
No (n = 1914) Placebo 97 8.86 10.95 1 0.02
Praziquantel 90 9.07 9.92 0.90 (0.60–1.35)
Yes (n = 421) Placebo 11 2.08 5.28 1
Praziquantel 27 1.92 14.06 2.65 (1.16–6.08)
Mpairwe et al. Deworming in pregnancy and allergy risk
Pediatric Allergy and Immunology 22 (2011) 305–312 ª 2011 John Wiley & Sons A/S 309
mix, Blomia tropicalis, egg and cow’s milk). Dermatophago-
ides mix and German cockroach IgE assays were performed
for 248 of these infants.
A positive SPT response to any allergen was strongly asso-
ciated with incidence of doctor-diagnosed eczema [HR (95%
CI), p-value: 6.07 (1.67–22.08), 0.006]. There were weak posi-
tive associations for both dust mite- and cockroach-speciﬁc
IgE with doctor-diagnosed eczema [HR 3.28 (0.63–17.15),
p = 0.16 and HR 1.79 (0.28–11.55), p = 0.54, respectively].
Discussion
We have shown for the ﬁrst time that treatment of pregnant
women with albendazole is associated with increased risk of
infantile eczema and that treatment with praziquantel is
associated with increased risk of eczema among infants of
mothers with S. mansoni infection. Our ﬁndings are consis-
tent with our preliminary study (17) and support the
hypothesis that maternal worms during pregnancy, or neo-
natal life and early breastfeeding, may protect against
allergy in infancy and that treatment of these worms during
pregnancy increases the risk of allergy. The effects of treat-
ment on reported allergy outcomes at 1 yr were similar to
those for doctor-diagnosed outcomes, suggesting good inter-
nal validity of the study. These results may be generalised
to communities with similar prevalence and intensity of
worm infections.
A possible cause of imprecision was the clinical diagnosis
of eczema. Study clinicians were not dermatologists and
tended to classify skin conditions that were not obviously
eczema as non-speciﬁc rash. Although such misclassiﬁcations
would have been balanced between treatment arms, this
may have led to underestimation of the incidence of eczema
and therefore to reduced power. The power of the study
was lower than expected for subgroup analyses because the
rate of eczema was lower than predicted, although the per-
son-years of follow-up were greater. Both SPT and allergen-
speciﬁc IgE responses of a sample of infants were positively
associated with doctor-diagnosed eczema, our main out-
come: these associations do not identify the causative aller-
gen for eczema in this study, but do indicate that it was
atopic in nature, and part of an atopic phenotype in these
children.
Hookworm was the commonest worm species among the
pregnant women and was highly susceptible to albendazole.
However, the observed strong effect of albendazole among
infants whose mothers had no hookworm detected was unex-
pected. Several possible hypotheses may be considered. First,
could the effect of albendazole have been mediated through
effects on undetected hookworm, or the presence of other
albendazole-susceptible geohelminths in the ‘hookworm-nega-
tive’ group? The Kato-Katz method is of low sensitivity when
a single stool sample is used (23), and this might be particu-
larly important given that the majority of hookworm infec-
tions in this setting were light (24). However, among mothers
in the albendazole-placebo group, 647 had at least three stool
samples examined before they were treated 6 wk post-deliv-
ery; evaluation of results from all three stool samples
increased the estimate of hookworm prevalence by only 6%
(from 45% to 51%). We also found an effect of albendazole
among infants whose mothers had neither hookworm nor
other susceptible, or partially susceptible, worm infections
(such as T. trichiura, S. stercoralis and A. lumbricoides).
Thus, an effect of albendazole on undiagnosed hookworm
infection, or other geohelminths, may not explain our result.
It seems more likely that albendazole itself when used during
pregnancy, or its effect on some other unidentiﬁed organism,
may have had immunological effects on the foetus. This is
plausible: albendazole acts by binding tubulin and inhibiting
the formation of microtubules in the cytoskeleton and can
affect not only worms, but also fungi, protozoa and mamma-
lian cells (25). The observed signiﬁcant trend of reduced
effect of albendazole on the risk of infantile eczema with
increasing number of worm species that a mother had also
suggests a possible protective effect of worms against detri-
mental effects of albendazole. These hypotheses require fur-
ther investigation. Thus, we have shown a clear adverse effect
of maternal treatment with albendazole on the incidence of
infantile eczema, but the role of elimination of worms in the
mechanism of this effect is not certain. Further trials using
anthelminthic drugs that differ in their mode of action would
be useful. By contrast, for praziquantel, the detrimental effect
of treatment was found only among infants of mothers with
schistosomiasis, suggesting a mechanism mediated by an
effect on maternal schistosome infections. This is consistent
with observational results suggesting a suppressive effect of
S. haematobium on skin prick test reactivity in children (7).
Of note, in the praziquantel placebo group, the rate of
eczema among infants of mothers with S. mansoni was lower
than the rate among those of mothers without schistosomia-
sis (Table 2). Thus, our results indicate a protective effect of
exposure to maternal schistosomiasis in utero against allergic
disease in infancy, reversed by maternal treatment.
Our results complement observational studies (26) and ani-
mal models (27) that suggest a protective effect of maternal
exposure to farm environment and to farm-related bacteria,
to now suggest a protective effect of maternal worms against
allergy in the offspring. Both human studies and animal
models suggest that exposure to farm bacteria acts by inﬂu-
encing the maternal cytokine milieu and thereby modulating
Toll-like receptor (TLR) expression in the placenta and foe-
tus (28). Worm infections also inﬂuence systemic TLR
expression and cytokine production (29) and might plausibly
act through a related pathway.
Our randomised intervention was provided during the
second or third trimester of pregnancy; all women were
de-wormed approximately 6 wk after delivery. Thus, the
comparison groups differed in their treatment status during
pregnancy and in their worm status during the remainder of
the pregnancy and the neonatal period. Differences in expo-
sure to drugs could have elicited effects during pregnancy,
and differences in exposure to maternal worms could have
elicited effects either before, or immediately after delivery.
However, our observations clearly demonstrate the impor-
tance of exposures very early in life for the development of
the infant immune system and for the protection against
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allergy. Foetal or neonatal imprinting may be more impor-
tant than exposures in later childhood, given the limited
effect observed following anthelminthic treatment in child-
hood on prevalence of atopy (9). Pregnancy may provide a
window of opportunity during which interventions to prevent
allergy could be initiated for children at risk. Research to
identify the underlying mechanisms of these effects is urgently
needed.
The long-term implications of our ﬁndings remain to be
determined through ongoing follow-up of the cohort and rep-
lication in other studies. A review published in 2007 reported
that the risk of developing asthma in childhood for children
with atopic eczema was one out of three (30). Wheeze during
the ﬁrst year of life may be caused by a variety of conditions
and is not diagnostic of asthma, although it is of interest that
anthelminthic treatment was also associated with an increase
in reported wheeze in infancy in this study. The implications
of our ﬁndings for the long-term risk of asthma are of great-
est concern because this condition may be fatal, particularly
in regions with poor health service resources (2).
Allergy prevalence is increasing globally, with no proven
cause, and our results suggest that worms may play a protec-
tive role. We therefore recommend that further studies should
be undertaken in areas of higher worm prevalence and inten-
sity to investigate whether the effects we have observed in
this study are replicated, and the underlying immunological
mechanisms of the effects.
We have presented results of the ﬁrst randomised-con-
trolled trial on the effects of anthelminthic treatment during
pregnancy on the risk of allergic disease among the offspring.
We have shown that interventions during pregnancy can
inﬂuence risk of infantile eczema, although the mechanism of
action is not entirely clear. The detrimental effects of treat-
ment suggest that worm infections during pregnancy or neo-
natal life may have a role in protecting against allergy in
infancy. Worms or worm products could have a role in the
primary prevention of allergic disease.
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